Want to see KRYS full AI Analyst Report?
KRYS Stock Chart & Stats
$335.19
$7.69(2.35%)
At close: 4:00 PM EDT
$335.19
$7.69(2.35%)
Day’s Range― - ―
52-Week Range$130.50 - $382.54
Previous CloseN/A
Volume520.38K
Average Volume (3M)527.57K
Market Cap
$10.81B
Enterprise Value$7.07K
Total Cash (Recent Filing)$823.40M
Total Debt (Recent Filing)$9.11M
Price to Earnings (P/E)44.0
Beta0.76
Next Earnings
Aug 03, 2026EPS Estimate
1.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)7.75
Shares Outstanding29,479,755
10 Day Avg. Volume847,932
30 Day Avg. Volume527,571
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)5.85
Price to Sales (P/S)18.34
P/FCF Ratio37.77
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$358.89Price Target Upside7.07% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)7.5
Revenue Forecast (FY)$511.66M
Bulls Say, Bears Say
Bulls Say
High Gross Margins & ProfitabilitySustained extremely high gross margins and current operating/net profitability provide durable cash generation per unit sold for a biologic gene therapy. This supports reinvestment in commercialization and R&D while insulating core economics from moderate pricing pressure.
Strong Cash Generation And Conservative Balance SheetA large cash reserve, robust free cash flow run rate and negligible debt materially reduce financial risk and fund multi-year clinical and commercial expansion without near-term financing. This enhances strategic optionality and resilience to cyclical setbacks.
Platform/regulatory Advantages And Busy PipelinePlatform designations and a deep, staged pipeline create structural optionality: streamlined regulatory interactions, cadence of registrational readouts, and potential label expansions increase probability of additional approvals and diversified future revenue streams.
Bears Say
Revenue Predictability Vs Payer DynamicsReliance on payer approvals and maintenance dosing patterns creates recurring revenue variability across quarters. Persistent start/stop dynamics reduce forecasting reliability and require ongoing commercial investment to stabilize adherence and payer relationships for durable uptake.
European Pricing And Reimbursement UncertaintyUnresolved reimbursement negotiations in major EU markets pose structural risk to international revenue scaling. Negative or delayed pricing outcomes would limit patient access, compress margin realization abroad, and slow the company’s ability to monetize its launch investments.
Historical Earnings And Cash Flow VolatilityAlthough current profitability and cash flow are strong, a short track record of sustained positive results and prior multi-year losses signal execution and market risks. The company must sustain commercial growth to prove earnings durability across cycles.
Krystal Biotech News
KRYS FAQ
What was Krystal Biotech’s price range in the past 12 months?
Krystal Biotech lowest stock price was $130.50 and its highest was $382.54 in the past 12 months.
What is Krystal Biotech’s market cap?
Krystal Biotech’s market cap is $10.81B.
When is Krystal Biotech’s upcoming earnings report date?
Krystal Biotech’s upcoming earnings report date is Aug 03, 2026 which is in 2 days.
How were Krystal Biotech’s earnings last quarter?
Krystal Biotech released its earnings results on May 04, 2026. The company reported $1.83 earnings per share for the quarter, beating the consensus estimate of $1.49 by $0.34.
Is Krystal Biotech overvalued?
According to Wall Street analysts Krystal Biotech’s price is currently Undervalued.
Does Krystal Biotech pay dividends?
Krystal Biotech does not currently pay dividends.
What is Krystal Biotech’s EPS estimate?
Krystal Biotech’s EPS estimate is 1.73.
How many shares outstanding does Krystal Biotech have?
Krystal Biotech has 29,479,755 shares outstanding.
What happened to Krystal Biotech’s price movement after its last earnings report?
Krystal Biotech reported an EPS of $1.83 in its last earnings report, beating expectations of $1.49. Following the earnings report the stock price went up 7.86%.
Which hedge fund is a major shareholder of Krystal Biotech?
Currently, no hedge funds are holding shares in KRYS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Krystal Biotech Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$358.89 (7.07% Upside)
$358.89 (7.07% Upside)
Blogger Sentiment
Bullish
KRYS Sentiment 100%
Sector Average 65%
Sector Average 65%
Hedge Fund Trend
Increased
By 74.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $15.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.3%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
123.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
30.02%
Trailing 12-Months
Company Description
Krystal Biotech
Krystal Biotech, Inc. (KRYS) is a commercial-stage biotechnology company focused on developing and commercializing genetic medicines using a proprietary herpes simplex virus type 1 (HSV-1)–based gene delivery platform. The company’s lead commercial product is VYJUVEK (beremagene geperpavec-svdt), a topical gene therapy for dystrophic epidermolysis bullosa (DEB), a rare genetic skin disorder. Krystal also advances additional HSV-1–based genetic medicine programs for other rare diseases through internal development.
KRYS Company Deck
KRYS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial momentum, robust profitability, a growing international launch and a busy clinical pipeline with multiple near-term readouts and regulatory designations — balanced by operational challenges including insurance switchovers, start-stop treatment dynamics, rising G&A, certain program-specific regulatory/timing requirements, and ongoing European pricing negotiations. Overall the positives (revenue growth, high gross margin, strong cash position, multiple upcoming data readouts and regulatory designations) materially outweigh the operational and timing headwinds described.View all KRYS earnings summariesKRYS Stock 12 Month Forecast
Average Price Target
$358.89
▲(7.07% Upside)
Technical Analysis
Ownership Overview
11.14% Insiders
30.42% Mutual Funds
3.40% Other Institutional Investors
32.55% Public Companies and Individual Investors